UpToDate vs Micromedex: cost, drug database coverage and which one your hospital actually needs

Neither one will tell you. This is the unusual thing about this particular head-to-head: in most comparisons at least one vendor publishes a number you can read without talking to a salesperson, and here neither does. We checked both vendors' own pages again in August 2026. The UpToDate store returns no dollar figure anywhere on the page, and instead routes you through a country selector and a professional-role selector before it will quote you. The Micromedex product pages carry no dollar figure at any tier either.

The two do differ in one practical way. UpToDate has a real individual purchase path: an individual clinician can go to the store, identify their country and role, and come out with a personal subscription, even though the price is not visible in advance. Micromedex has no equivalent consumer route at all. It is sold to organizations, quoted on user count, modules and contract term, and an individual pharmacist cannot simply buy a seat. If you want your own access rather than access through an employer, that asymmetry decides it before cost enters the picture.

For group buying, Wolters Kluwer states plainly that organizations with 20 or more users should go to enterprise sales rather than buying seats, which is the clearest public threshold either vendor gives. You will find confident annual figures for both products on software directory sites. Those numbers are not vendor-published, they contradict each other, and we do not repeat them. Our fuller breakdowns are in what UpToDate actually costs and what Micromedex actually costs, and the contract mechanics are in our guide to institutional and group licensing.

The pattern is worth naming because it repeats across this category: price transparency tracks who the buyer is, not how good the product is. Anything sold to a clinician with a credit card carries a published price, which is why Lexidrug shows $29.99 a month on the App Store. Anything sold to a procurement department does not. UpToDate and Micromedex are both procurement products, so both stay quiet, and that says nothing about which one is better.

The cleanest way to hold the difference in your head is by the question each was built to answer. UpToDate answers how a condition is worked up and treated. You arrive with a clinical problem, such as a new atrial fibrillation diagnosis or a suspected pulmonary embolism, and you leave with a graded, referenced view of what to do next. Micromedex answers what you need to know about a drug. You arrive with a medication and leave with dosing, stability, compatibility, toxicity and the evidence behind them.

That is why the two rarely feel interchangeable to the people using them. A hospitalist who loses UpToDate loses their treatment reference. A pharmacist who loses Micromedex loses the ability to answer whether two infusions can share a line, what to do about an overdose, and how to compound something safely. Merative names pharmacy, nursing, physicians and advanced practice clinicians, toxicology teams, academic users, health IT, government and health plans as distinct audiences, and the toxicology and compounding audiences in particular have nowhere else obvious to go.

There is one wrinkle worth knowing. UpToDate's drug content is not independent of the compendium market: it comes from Lexidrug, the product formerly called Lexicomp, which Wolters Kluwer also owns. So comparing UpToDate's drug monographs to Micromedex is really comparing Lexidrug to Micromedex with a different wrapper, which we cover directly in Lexicomp versus Micromedex. If your question is specifically about drug content depth rather than disease coverage, that is the more useful comparison, and UpToDate versus Lexicomp explains how the same vendor ended up selling both.

A great many US health systems license both, and it is usually a defensible decision rather than a procurement failure. The two cover different halves of the clinical question, and the departments that depend on them are different departments. Cutting Micromedex to keep UpToDate tends to land entirely on pharmacy. Cutting UpToDate to keep Micromedex tends to land entirely on the medical staff. Neither saving is as clean as it looks on the budget line.

The honest test is to look at what your people actually search for. If your drug information pharmacists field regular questions about IV compatibility, compounding stability, neonatal dosing or overdose management, a disease reference will not cover those and you need a drug compendium. If your clinicians are mostly asking diagnostic and treatment questions, a compendium will not cover those and you need a disease reference. Where an institution genuinely has both needs, the real question at renewal is not which one to drop but whether the drug compendium should be Micromedex or Lexidrug, since the second is frequently cheaper to add where UpToDate is already licensed.

What does duplicate, and is worth auditing, is overlap at the shallow end. Both resources answer routine interaction and dosing questions perfectly well, and so does the free tier of several other tools. If most of your usage volume is routine lookups rather than the deep questions only one of these can answer, you are paying compendium prices for compendium-grade depth you rarely reach. Our guide to the best clinical decision support software lays out the full field, and the role-by-role picture is in our guide to the best drug reference apps.

For a hospital pharmacist working at the top of their scope, Micromedex is generally the more useful of the two, and its 2026 Best in KLAS ranking for point-of-care drug reference reflects that. The work that defines the role, verifying orders, answering compatibility questions, supporting compounding, handling toxicological exposures and writing drug information responses, is drug work, and Micromedex is a drug resource with an accredited editorial process, in-line referencing and daily updates behind it.

That said, pharmacists in ambulatory or clinic settings often find the balance tips the other way, because their questions skew toward whether a therapy is appropriate for a condition at all. And in institutions running Epic, MEDITECH or Cerner, what is already surfaced inside the EHR frequently matters more than which database is objectively deeper, since a resource nobody can reach in three clicks does not get used. Our page on drug interaction checkers for pharmacists works through the practical version of this decision.

Both are tertiary sources, which matters when you are writing a formal drug information response or defending a formulary decision. The expectation in those settings is that you trace a claim back through the compendium to the primary study rather than cite the compendium as the last word. Both support that, since both reference the literature they are built from. We work through the full hierarchy in is Micromedex a tertiary source.

Both resources are excellent at answering a question you have already thought to ask. Neither one watches the order in front of you and volunteers, unprompted, that this patient is already on something that interacts with it, that their kidney function makes the standard dose wrong, or that a documented allergy rules out the obvious first choice. Getting all of that out of a reference means knowing to run several separate lookups in a row, and prescribing errors cluster precisely where nobody thought to look.

That is the narrow job Prescriber.io is built for. You enter the drug or the scenario once and it checks for drug-drug interactions, flags contraindications and allergy blockers, surfaces renal and hepatic dose adjustments, and suggests guideline-based alternatives, together, with a cited source on each flag so you can confirm it. It is decision-support, not autonomous prescribing: every flag is a prompt for a licensed clinician who reviews it, verifies against official sources, and signs. We do not carry IV compatibility data, compounding stability figures or toxicology monographs, and we are not a disease reference, so this sits alongside a compendium rather than replacing one. If you are weighing whether a given contract still earns its line item, our UpToDate alternative and Micromedex alternative pages cover that question directly.